120 related articles for article (PubMed ID: 7656487)
1. Effect of an ACTH(4-9) analogue on cisplatin neuropathy of longstanding duration: a phase II study.
Hilkens PH; van der Burg ME; Moll JW; van den Bent MJ; van Putten WL; Vecht CJ
Clin Neurol Neurosurg; 1995 May; 97(2):139-41. PubMed ID: 7656487
[TBL] [Abstract][Full Text] [Related]
2. The effects of an ACTH (4-9) analogue on development of cisplatin neuropathy in testicular cancer: a randomized trial.
van Gerven JM; Hovestadt A; Moll JW; Rodenburg CJ; Splinter TA; van Oosterom AT; Keizer L; Drogendijk TE; Groenhout CM; Vecht CJ
J Neurol; 1994 Jun; 241(7):432-5. PubMed ID: 7931444
[TBL] [Abstract][Full Text] [Related]
3. The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo.
Hovestadt A; van der Burg ME; Verbiest HB; van Putten WL; Vecht CJ
J Neurol; 1992 Mar; 239(3):143-6. PubMed ID: 1315383
[TBL] [Abstract][Full Text] [Related]
4. A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer.
Roberts JA; Jenison EL; Kim K; Clarke-Pearson D; Langleben A
Gynecol Oncol; 1997 Nov; 67(2):172-7. PubMed ID: 9367703
[TBL] [Abstract][Full Text] [Related]
5. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer.
van der Hoop RG; Vecht CJ; van der Burg ME; Elderson A; Boogerd W; Heimans JJ; Vries EP; van Houwelingen JC; Jennekens FG; Gispen WH
N Engl J Med; 1990 Jan; 322(2):89-94. PubMed ID: 2152972
[TBL] [Abstract][Full Text] [Related]
6. Neurotoxicity is not enhanced by increased dose intensities of cisplatin administration.
Hilkens PH; van der Burg ME; Moll JW; Planting AS; van Putten WL; Vecht CJ; van den Bent MJ
Eur J Cancer; 1995; 31A(5):678-81. PubMed ID: 7640038
[TBL] [Abstract][Full Text] [Related]
7. Rationale for the use of the ACTH4-9 analogue ORG 2766 in the treatment of diabetic neuropathy.
Bravenboer B; Erkelens DW; Gispen WH
Neth J Med; 1992 Dec; 41(5-6):255-8. PubMed ID: 1337372
[No Abstract] [Full Text] [Related]
8. ACTH/MSH like peptides in the treatment of cisplatin neuropathy.
Gispen WH; Hamers FP; Vecht CJ; Jennekens FG; Neyt JP
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):179-83. PubMed ID: 1326318
[TBL] [Abstract][Full Text] [Related]
9. Protection of cisplatin-induced neuropathy: recent developments.
Hamers F; Neijt J; Gispen W
Pathol Biol (Paris); 1992 Nov; 39(9):829-30. PubMed ID: 1311436
[No Abstract] [Full Text] [Related]
10. A single injection of a biodegradable microsphere formulation of the ACTH-(4-9) analogue ORG 2766 accelerates functional recovery after brain damage.
Wolterink G; Bouwman TR; Eenink MJ; De Nijs H; van Ree JM
J Pharm Pharmacol; 1990 Jul; 42(7):508-10. PubMed ID: 1980295
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of the neuropeptide ORG.2766 in the prevention and treatment of cisplatin-induced neurotoxicity in rats.
Gerritsen van der Hoop R; de Koning P; Boven E; Neijt JP; Jennekens FG; Gispen WH
Eur J Cancer Clin Oncol; 1988 Apr; 24(4):637-42. PubMed ID: 2838292
[TBL] [Abstract][Full Text] [Related]
12. An ACTH-(4-9) analogue, Org 2766, improves recovery from acrylamide neuropathy in rats.
Sporel-Ozakat RE; Edwards PM; Van der Hoop RG; Gispen WH
Eur J Pharmacol; 1990 Sep; 186(2-3):181-7. PubMed ID: 1963145
[TBL] [Abstract][Full Text] [Related]
13. Co-administration of the neurotrophic ACTH(4-9) analogue, ORG 2766, may reduce the cochleotoxic effects of cisplatin.
de Groot JC; Hamers FP; Gispen WH; Smoorenburg GF
Hear Res; 1997 Apr; 106(1-2):9-19. PubMed ID: 9112103
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin-induced neuropathy in mature rats: effects of the melanocortin-derived peptide ORG 2766.
Hamers FP; Pette C; Bravenboer B; Vecht CJ; Neijt JP; Gispen WH
Cancer Chemother Pharmacol; 1993; 32(2):162-6. PubMed ID: 8387400
[TBL] [Abstract][Full Text] [Related]
15. Randomized double-blind placebo-controlled trial to evaluate the effect of the ACTH4-9 analogue ORG 2766 in IDDM patients with neuropathy.
Bravenboer B; Hendrikse PH; Oey PL; van Huffelen AC; Groenhout C; Gispen WH; Erkelens DW
Diabetologia; 1994 Apr; 37(4):408-13. PubMed ID: 8063043
[TBL] [Abstract][Full Text] [Related]
16. [Use of semax at a follow-up of patients with posthypoxic encephalopathy].
Alekseeva GV; Bottaev NA; Goroshkova VV
Anesteziol Reanimatol; 1999; (1):40-3. PubMed ID: 10199046
[TBL] [Abstract][Full Text] [Related]
17. Neurotrophic effects of ACTH/MSH neuropeptides.
de Wied D
Acta Neurobiol Exp (Wars); 1990; 50(4-5):353-66. PubMed ID: 1966658
[TBL] [Abstract][Full Text] [Related]
18. Interventions for preventing neuropathy caused by cisplatin and related compounds.
Albers J; Chaudhry V; Cavaletti G; Donehower R
Cochrane Database Syst Rev; 2007 Jan; (1):CD005228. PubMed ID: 17253547
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity.
Gandara DR; Perez EA; Weibe V; De Gregorio MW
Semin Oncol; 1991 Feb; 18(1 Suppl 3):49-55. PubMed ID: 1848372
[TBL] [Abstract][Full Text] [Related]
20. ACTH analogue application to oncostatic chemotherapy. A double blind approach.
Piazza E; Cattaneo MT; Colombo F; Libretti A
Ric Clin Lab; 1984; 14(2):257-9. PubMed ID: 6091252
[No Abstract] [Full Text] [Related]
[Next] [New Search]
